AVAH Stock Forecast & Price Target

Aveanna Healthcare Hldgs is well positioned to benefit from durable demand for home-based care, especially in its core Private Duty Services business, where Medicaid and Medicaid MCO reimbursement support a large, medically complex patient base. Management’s higher long-term growth targets, strong 2Q results, and expected double-digit annual revenue growth, combined with preferred payor penetration at 64% of PDS MCO volume and 81% episodic mix in Home Health, point to improving visibility and margin resilience. The California Medi-Cal PDN rate increase effective January 2027, along with OBBBA-related insulation from Medicaid cuts and cash flow that supports delevering and tuck-in acquisitions, strengthens the fundamental case.

Aveanna Healthcare Hldgs is viewed negatively because a secondary offering of 15,000,000 shares at $11.75 on August 20th, 2026 was sold entirely by existing stockholders, with no proceeds going to the company and an additional 2,250,000-share over-allotment possible, which can pressure the stock. Its core business remains highly exposed to Medicaid and Medicaid MCO reimbursement, while the cited risks around government reimbursement, policy changes, nurse availability, regulatory/audit issues, and M&A execution all threaten earnings quality. The downside cases also imply that if labor headwinds trim 10% from base case FY27 adjusted EBITDA and legislative rate initiatives stall, valuation could contract to about 8x downside EBITDA, reinforcing a fragile fundamental setup.